0001209191-17-058479.txt : 20171031 0001209191-17-058479.hdr.sgml : 20171031 20171031181502 ACCESSION NUMBER: 0001209191-17-058479 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171031 FILED AS OF DATE: 20171031 DATE AS OF CHANGE: 20171031 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chodakewitz Jeffrey CENTRAL INDEX KEY: 0001610876 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 171166867 MAIL ADDRESS: STREET 1: C/O TETRAPHASE PHARMACEUTICALS, INC. STREET 2: 480 ARSENAL ST., SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-10-31 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001610876 Chodakewitz Jeffrey C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP GMDA, CMO Common Stock 2017-10-31 4 S 0 1400 142.38 D 113024 D Common Stock 2017-10-31 4 S 0 4100 143.46 D 108924 D Common Stock 2017-10-31 4 S 0 25784 144.46 D 83140 D Common Stock 2017-10-31 4 S 0 19016 145.26 D 64124 D Common Stock 2017-10-31 4 S 0 4700 146.52 D 59424 D Common Stock 2017-10-31 4 S 0 3400 147.75 D 56024 D Common Stock 2017-10-31 4 S 0 1400 148.40 D 54624 D Common Stock 2017-10-31 4 S 0 200 149.34 D 54424 D Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $142.38 (range $141.83 to $142.81). Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $143.46 (range $142.87 to $143.85). Open market sales reported on this line occurred at a weighted average price of $144.46 (range $143.90 to $144.89). Open market sales reported on this line occurred at a weighted average price of $145.26 (range $144.91 to $145.87). Open market sales reported on this line occurred at a weighted average price of $146.52 (range $146.16 to $147.14). Open market sales reported on this line occurred at a weighted average price of $147.75 (range $147.18 to $148.15). Open market sales reported on this line occurred at a weighted average price of $148.40 (range $148.19 to $148.70). /s/ Omar White, Attorney-in-Fact 2017-10-31